Integrated BioPharma (OTCQX: INBP) hires veteran ops leader

Rhea-AI Filing Summary

INTEGRATED BIOPHARMA, INC. (INBP) reported that its wholly owned subsidiary, Manhattan Drug Company, Inc. (MDC), has appointed Michael G. Richtmyer as Head of Operations. He joined MDC on August 3, 2026 and brings more than 35 years of senior operations and general management experience across pharmaceutical, nutraceutical, supplement, personal care, and contract manufacturing sectors.

Richtmyer will oversee operational strategy and execution at MDC, focusing on manufacturing performance, supply chain reliability, quality systems, productivity, and scalable growth. He previously served as President of Tishcon Corp., where he managed two vitamin, mineral, and supplement contract manufacturing sites and operations for more than 650 active products, and earlier worked with Integrated BioPharma from 1991 to 1999.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Appointment date: August 3, 2026 Experience: more than 35 years Active products managed: more than 650 +2 more

5 metrics

Appointment date August 3, 2026 Date Michael G. Richtmyer joined MDC as Head of Operations

Experience more than 35 years Senior operations and general management experience cited for Michael G. Richtmyer

Active products managed more than 650 Number of active products managed at two contract manufacturing sites while President of Tishcon Corp.

Trading symbol INBP Integrated BioPharma, Inc. trades on OTCQX under this symbol

Press release date August 20, 2026 Date of the news release announcing Michael Richtmyer’s appointment

Key Terms

contract manufacturer, nutraceutical, operational performance metrics, forward-looking statements, +1 more

5 terms

contract manufacturer financial

"MDC is a contract manufacturer of vitamins and nutritional supplements"

A contract manufacturer is a company hired to produce goods or products for another company under a contractual agreement, often using the hiring company's designs and specifications. Investors watch them because they affect costs, product quality and supply reliability—similar to outsourcing baking to a specialized bakery: if the baker is fast and consistent, the brand can grow with lower overhead; if not, sales and profits can suffer.

nutraceutical medical

"experience across the pharmaceutical, nutraceutical, mineral, supplement, personal care"

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

operational performance metrics technical

"established operational performance metrics, and oversaw quality and environmental"

forward-looking statements regulatory

"This document contains forward-looking statements within the meaning of the Private"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"within the meaning of the Private Securities Litigation Reform Act of 1995"

FAQ

What executive leadership change did INBP announce at its subsidiary MDC?

Integrated BioPharma’s subsidiary MDC appointed Michael G. Richtmyer as Head of Operations, effective when he joined on August 3, 2026. He will lead manufacturing, supply chain, quality systems, productivity, and scalable growth initiatives across MDC’s operations.

What is Michael Richtmyer’s background relevant to INBP (INBP)?

Michael Richtmyer has over 35 years of senior operations and general management experience across pharmaceutical, nutraceutical, supplement, personal care, and contract manufacturing sectors, including prior work at Integrated BioPharma from 1991 to 1999 and serving as President of Tishcon Corp.

What responsibilities will Michael Richtmyer have at Manhattan Drug Company, part of INBP?

As Head of Operations at MDC, Michael Richtmyer will direct operational strategies across manufacturing performance, supply chain reliability, quality systems, productivity, and scalable growth, including oversight of planning processes, performance metrics, and organizational and systems improvements.

How does Integrated BioPharma (INBP) describe the business of its subsidiary MDC?

Manhattan Drug Company (MDC) is described as a contract manufacturer of vitamins and nutritional supplements, producing products for distributors, multilevel marketers, and specialized health-care providers, aligning with Integrated BioPharma’s broader focus on vitamins, nutritional supplements, and herbal products.

On which market does Integrated BioPharma, Inc. (INBP) trade and what is its focus?

Integrated BioPharma, Inc. trades under symbol INBP on the OTCQX market. It is engaged primarily in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products through its operating subsidiaries, including MDC.

What prior role did Michael Richtmyer hold before joining INBP’s subsidiary MDC?

Before joining MDC, Michael Richtmyer served as President of Tishcon Corp., where he had full operational, quality, sales, and budgetary responsibility for two contract manufacturing sites producing softgels, capsules, tablets, powders, and turnkey packaging for more than 650 products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/20/2026 - 03:27 PM Accepted by SEC EDGAR 08/20/2026 - 03:27 PM Learn about SEC filing dates

false 0001016504 0001016504 2026-08-20 2026-08-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

August 20, 2026

________________

INTEGRATED BIOPHARMA, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Delaware

(STATE OR OTHER JURISDICTION OF INCORPORATION)

001-31668	22-2407475
(COMMISSION FILE NUMBER)	(I.R.S. EMPLOYER IDENTIFICATION NO.)

225 Long Avenue

Hillside, New Jersey 07205

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(973) 926-0816

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Table of Contents

Item 8.01  OTHER EVENTS.

On August 20, 2026, Integrated BioPharma, Inc. (the "Company") and Manhattan Drug Company, Inc. ("MDC"), a wholly owned subsidiary of the Company, issued a press release announcing the appointment of Michael Richtmyer as Head of Operations of MDC.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS

(d)           Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1		Press Release Dated August 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-1-

Table of Contents

EXHIBIT INDEX

Exhibit		Description
99.1		Press Release Dated August 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTEGRATED BIOPHARMA, INC.
Date: August 20, 2026	By:     /s/ Dina L Masi
	Dina L Masi
	Chief Financial Officer

-3-

Table of Contents

-3-

EXHIBIT 99-1

NEWS RELEASE for August 20, 2026

Contact: Dina Masi, CFO

Integrated BioPharma, Inc.

investors@ibiopharma.com

888.319.6962

INTEGRATED BIOPHARMA'S WHOLLY-OWNED SUBSIDIARY, MANHATTAN DRUG COMPANY, INC. APPOINTS MICHAEL RICHTMYER AS HEAD OF OPERATIONS

HILLSIDE, NEW JERSEY (August 20, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) — Manhattan Drug Company, Inc. (“MDC”), a wholly owned subsidiary of Integrated BioPharma, Inc. (the “Company”) announces that Michael G. Richtmyer joined the Company on August 3, 2026 as Head of Operations for MDC. Mr. Richtmyer is an experienced senior operations leader, bringing more than 35 years of stewardship in manufacturing, supply chain, quality, and organizational transformation.

Mr. Richtmyer will lead operational strategies and execution across MDC, with a focus on manufacturing performance, supply chain reliability, quality systems, productivity, and scalable growth.

Mr. Richtmyer brings more than three decades of senior operations and general management experience across the pharmaceutical, nutraceutical, mineral, supplement, personal care, and contract manufacturing sectors. His background includes leading multisite manufacturing and distribution organizations, improving profitability, strengthening customer relationships, and guiding organizations through growth, integration, and operational change.

“Michael’s deep operational expertise and proven ability to improve performance across complex manufacturing environments make him an outstanding addition to MDC. His leadership will help advance our commitment to operational excellence, quality, customer service, and long-term growth.”, stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.

Most recently, Richtmyer served as President of Tishcon Corp., where he held full operational, quality, sales, and budgetary responsibility for two vitamin, mineral, and supplement contract manufacturing sites. There, he managed operations producing softgels, capsules, tablets, and powders, including turnkey packaging solutions for more than 650 active products.

Throughout his career, Mr. Richtmyer held various senior positions at several branded and contract manufacturing companies, specializing in vitamins, minerals, supplements and personal care manufacturing, and the pharmaceutical industry. He led manufacturing, packaging, engineering, maintenance, supply chain, purchasing, quality, information technology, and third-party manufacturing. He implemented new planning processes, updated manufacturing routing and product costing models, established operational performance metrics, and oversaw quality and environmental, health, and safety compliance with federal and state regulatory agencies.

Mr. Richtmyer previously worked with the Company from 1991 to 1999 and now returns with expanded leadership experience in manufacturing operations, supply chain strategy, quality oversight, business transformation, ERP implementation, capital planning, and organizational development.

“I am excited to return to MDC and contribute to its next phase of operational growth,” said Mr. Richtmyer. “I look forward to working with the team to build on the Company’s foundation, strengthen execution, and deliver reliable, high-quality service to customers, Mr. Richtmyer further stated.”

MDC is a contract manufacturer of vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 PRESS RELEASE AUGUST 20 2026 10.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 10.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 13.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.1 KB